Key result
Antioxidant therapy is a promising strategy for pulmonary hypertension treatment, though favorable preclinical outcomes have not been consistently reproduced in clinical practice.
Why the study?
Antioxidant therapy shows promise in preclinical PH studies, but favorable outcomes have not been consistently reproduced in clinical practice.
Does antioxidant therapy improve outcomes in pulmonary hypertension?
Does antioxidant therapy improve outcomes in pulmonary hypertension?
While oxidative stress plays a critical role in pulmonary hypertension pathogenesis, antioxidant therapy has not yet shown consistent clinical benefit despite preclinical promise.
Highlights oxidative stress as PH target; leaves open antioxidant efficacy in trials.
Pulmonary hypertension (PH) is a progressive disease characterized by elevated artery pressures and pulmonary vascular resistance. Underlying mechanisms comprise endothelial dysfunction, pulmonary artery remodeling and vasoconstriction. Several studies have shown evidence of the critical role of oxidative stress in PH pathophysiology. Alteration of redox homeostasis produces excessive generation of reactive oxygen species, inducing oxidative stress and the subsequent alteration of biological molecules. Exacerbations in oxidative stress production can lead to alterations in nitric oxide signaling pathways, contributing to the proliferation of pulmonary arterial endothelial cells and smooth muscle cells, inducing PH development. Recently, antioxidant therapy has been suggested as a novel therapeutic strategy for PH pathology. However, the favorable outcomes observed in preclinical studies have not been consistently reproduced in clinical practice. Therefore, targeting oxidative stress as a therapeutic intervention for PH is an area that is still being explored. This review summarizes the contribution of oxidative stress to the pathogenesis of the different types of PH and suggests antioxidant therapy as a promising strategy for PH treatment.
No takes yet. Share an insight, caveat, or question.
Poyatos et al. (2023) conducted a review in Pulmonary hypertension. Antioxidant therapy was evaluated. Antioxidant therapy is a promising strategy for pulmonary hypertension treatment, though favorable preclinical outcomes have not been consistently reproduced in clinical practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: